Cell therapy launched for knee osteoarthritisSHALBY - 314 Change: 7.35 (2.39 %)
According to Business Standard, Alkem and Stempeutics, are launching the first off-the-shelf stem cell therapy, StemOne for treating patients with osteoarthritis. The therapy is priced at ~Rs 1.25 lakh for a single injection and the effects can last up to two years or more in a patient progressively seeing wear and tear of the cartilage in the knee.
This treatment is meant for patients wanting to avoid knee surgeries and seems to be confined to mid term relief. We do not perceive this as a direct threat to Shalby's potential.